| Literature DB >> 33684637 |
Richard L Wasserman1, Jeffrey Factor2, Hugh H Windom3, Elissa M Abrams4, Philippe Begin5, Edmond S Chan6, Matthew Greenhawt7, Nathan Hare8, Douglas P Mack9, Lyndon Mansfield10, Moshe Ben-Shoshan11, David R Stukus12, Timothy Vander Leek13, Marcus Shaker14.
Abstract
Oral immunotherapy (OIT) provides an active treatment option for patients with food allergies. OIT may improve quality of life and raise the threshold at which a patient with food allergy may react to an allergen, but it is a rigorous therapy that requires a high degree of commitment by the clinician, patients, and families. Recent guidelines from the Canadian Society for Allergy and Clinical Immunology have provided a framework for the ethical, evidence-based, and patient-oriented clinical practice of OIT, and the European Academy of Allergy, Asthma, and Immunology guidelines have also recommended that OIT can be used as a potential treatment. The recent Food and Drug Administration approval of an OIT pharmaceutical has accelerated the adoption of OIT. This review provides a summary of the recent Canadian Society for Allergy and Clinical Immunology guidelines and a consensus of practical experience of clinicians across the United States and Canada related to patient selection, office and staff preparation, the general OIT process, OIT-related reaction management, and treatment outcomes.Entities:
Keywords: Adverse reactions; OIT (oral immunotherapy); Practical experience; Protocol considerations; Shared decision making
Year: 2021 PMID: 33684637 DOI: 10.1016/j.jaip.2021.02.046
Source DB: PubMed Journal: J Allergy Clin Immunol Pract